Regression of glomerular and tubulointerstitial injuries by dietary salt reduction with combination therapy of angiotensin II receptor blocker and calcium channel blocker in Dahl salt-sensitive rats

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Rafiq, Kazi ^a   Nishiyama, Akira ^a   Konishi, Yoshio ^b   Morikawa, Takashi ^b   Kitabayashi, Chizuko ^b   Kohno, Masakazu ^a   Masaki, Tsutomu ^a   Mori, Hirohito ^a   Kobori, Hiroyuki ^a   Imanishi, Masahito ^b  

^a KAGAWA UNIVERSITY   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZELNIDIPINE; HYDRALAZINE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZETIDINE 2 CARBOXYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CYTOKINE; DIHYDROPYRIDINE DERIVATIVE; IMIDAZOLE DERIVATIVE; MINERALOCORTICOID RECEPTOR; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GLOMERULAR INJURY; GLOMERULOPATHY; GLOMERULOSCLEROSIS; HYPERTENSION; INFLAMMATORY CELL; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY TUBULE DAMAGE; MALE; MCP 1 GENE; NONHUMAN; PAI 1 GENE; PODOCYTE; PROTEINURIA; RAT; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TUBULOINTERSTITIAL INJURY; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD PRESSURE; COMPLICATION; DAHL RAT; DRUG SCREENING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; GLOMERULUS; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL INSUFFICIENCY;

RATTUS;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; AZETIDINECARBOXYLIC ACID; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; COMBINED MODALITY THERAPY; CYTOKINES; DIET, SODIUM-RESTRICTED; DIHYDROPYRIDINES; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; GENE EXPRESSION REGULATION; HYPERTENSION; IMIDAZOLES; KIDNEY GLOMERULUS; MALE; NADPH OXIDASE; RATS, INBRED DAHL; RECEPTORS, MINERALOCORTICOID; RENAL INSUFFICIENCY; TETRAZOLES;

EID: 84907280003     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107853     Document Type: Article

References (45)

1. Wajchenberg BL, Sabbaga E, Fonseca JA (1983) The natural history of diabetic nephropathy in type I diabetes and the role of metabolic control in its prevention, reversibility and clinical course. Acta Diabetol Lat 20: 1-18.
2. Klahr S, Schreiner G, Ichikawa I (1988) The progression of renal disease. N Engl J Med 318: 1657-1666.
3. Smadel JE (1937) Experimental Nephritis in Rats Induced by Injection of Anti-Kidney Serum: Iii. Pathological Studies of the Acute and Chronic Disease. J Exp Med 65: 541-555.
4. Sugimoto H, LeBleu VS, Bosukonda D, Keck P, Taduri G, et al. (2012) Activinlike kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 18: 396-404.
5. Ma LJ, Nakamura S, Aldigier JC, Rossini M, Yang H, et al. (2005) Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 16: 966-976.
6. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I (1991) Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 40: 195-202.
7. Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y (2002) Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis 39: 493-502.
8. Hayashi W, Obata Y, Nishino T, Abe S, Io K, et al. (2012) Glomerular repair retardation via blocking of angiotensin II type 1a receptor pathway in a mouse glomerulonephritis model. Nephron Exp Nephrol 122: 13-22.
9. Pichaiwong W, Hudkins KL, Wietecha T, Nguyen TQ, Tachaudomdach C, et al. (2013) Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. J Am Soc Nephrol 24: 1088-1102.
10. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M (1998) Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69-75.
11. Adamczak M, Gross ML, Krtil J, Koch A, Tyralla K, et al. (2003) Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 14: 2833-2842.
12. Ihara G, Kiyomoto H, Kobori H, Nagai Y, Ohashi N, et al. (2010) Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade. J Hypertens 28: 2289-2298.
13. Yamamoto E, Kataoka K, Dong YF, Koibuchi N, Toyama K, et al. (2012) Calcium channel blockers, more than diuretics, enhance vascular protective effects of Angiotensin receptor blockers in salt-loaded hypertensive rats. PLoS One 7: e39162.
14. Nagasu H, Satoh M, Yorimitsu D, Tomita N, Sasaki T, et al. (2011) Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats. Kidney Blood Press Res 34: 87-96.
15. Jinno T, Iwai M, Li Z, Li JM, Liu HW, et al. (2004) Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 43: 263-269.
16. Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, et al. (2011) Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertens Res 34: 935-941.
17. Kim-Mitsuyama S, Ogawa H, Matsui K, Jinnouchi T, Jinnouchi H, et al. (2013) An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. Kidney Int 83: 167-176.
18. Rafiq K, Sherajee SJ, Hitomi H, Nakano D, Kobori H, et al. (2013) Calcium Channel Blocker Enhances Beneficial Effects of an Angiotensin II AT1 Receptor Blocker against Cerebrovascular-Renal Injury in type 2 Diabetic Mice. PLoS One 8: e82082.
19. Bledsoe G, Shen B, Yao Y, Zhang JJ, Chao L, et al. (2006) Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther 17: 545-555.
20. Fan YY, Kohno M, Nakano D, Hitomi H, Nagai Y, et al. (2009) Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats. J Hypertens 27: 1855-1862.
21. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, et al. (2012) Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 125: 1402-1413.
22. Nishiyama A, Yoshizumi M, Rahman M, Kobori H, Seth DM, et al. (2004) Effects of AT1 receptor blockade on renal injury and mitogen-activated protein activity in Dahl salt-sensitive rats. Kidney Int 65: 972-981.
23. Rafiq K, Nakano D, Ihara G, Hitomi H, Fujisawa Y, et al. (2011) Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats. J Hypertens 29: 290-298.
24. Ohashi N, Urushihara M, Satou R, Kobori H (2010) Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen species-ERK/JNK pathways. Hypertens Res 33: 1174-1181.
25. Ji C, Kozak KR, Marnett LJ (2001) IkappaB kinase, a molecular target for inhibition by 4-hydroxy-2-nonenal. J Biol Chem 276: 18223-18228.
26. Kobori H, Katsurada A, Ozawa Y, Satou R, Miyata K, et al. (2007) Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients. Biochem Biophys Res Commun 358: 156-163.
27. Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, et al. (2010) Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther 332: 1072-1080.
28. Vallon V, Lang F (2005) New insights into the role of serum- and glucocorticoidinducible kinase SGK1 in the regulation of renal function and blood pressure. Curr Opin Nephrol Hypertens 14: 59-66.
29. Park J, Leong ML, Buse P, Maiyar AC, Firestone GL, et al. (1999) Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. EMBO J 18: 3024-3033.
30. Chao J, Zhang JJ, Lin KF, Chao L (1998) Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl saltsensitive rats. Hum Gene Ther 9: 21-31.
31. Trolliet MR, Rudd MA, Loscalzo J (2001) Oxidative stress and renal dysfunction in salt-sensitive hypertension. Kidney Blood Press Res 24: 116-123.
32. Karlsen FM, Andersen CB, Leyssac PP, Holstein-Rathlou NH (1997) Dynamic autoregulation and renal injury in Dahl rats. Hypertension 30: 975-983.
33. Taylor NE, Glocka P, Liang M, Cowley AW Jr (2006) NADPH oxidase in the renal medulla causes oxidative stress and contributes to salt-sensitive hypertension in Dahl S rats. Hypertension 47: 692-698.
34. Shen B, Hagiwara M, Yao YY, Chao L, Chao J (2008) Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension 51: 1358-1365.
35. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ (2004) Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 286: F606-616.
36. Eddy AA (2000) Molecular basis of renal fibrosis. Pediatr Nephrol 15: 290-301.
37. Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784.
38. Zeisberg M, Neilson EG (2009) Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119: 1429-1437.
39. Carew RM, Wang B, Kantharidis P (2012) The role of EMT in renal fibrosis. Cell Tissue Res 347: 103-116.
40. Lv ZM, Wang Q, Wan Q, Lin JG, Hu MS, et al. (2011) The role of the p38 MAPK signaling pathway in high glucose-induced epithelial-mesenchymal transition of cultured human renal tubular epithelial cells. PLoS One 6: e22806.
41. Nakaya H, Sasamura H, Mifune M, Shimizu-Hirota R, Kuroda M, et al. (2002) Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats. Nephron 91: 710-718.
42. Kawarazaki H, Ando K, Fujita M, Matsui H, Nagae A, et al. (2011) Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats. Am J Physiol Renal Physiol 300: F1402-1409.
43. Kobori H, Harrison-Bernard LM, Navar LG (2001) Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J Am Soc Nephrol 12: 431-439.
44. Jaffe IZ, Mendelsohn ME (2005) Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 96: 643-650.
45. Teles F, Machado FG, Ventura BH, Malheiros DM, Fujihara CK, et al. (2009) Regression of glomerular injury by losartan in experimental diabetic nephropathy. Kidney Int 75: 72-79.